• Non ci sono risultati.

Scarica il programma

N/A
N/A
Protected

Academic year: 2022

Condividi "Scarica il programma"

Copied!
2
0
0

Testo completo

(1)

Consorzio Interuniversitario Nazionale per la Bio-Oncologia www.cinbo.org

DIRECTOR Clara Natoli SCIENTIFIC SECRETARIAT

Consiglia Carella Michele De Tursi Antonino Grassadonia

Nicola Tinari

SCIENTIFIC ADVISORY BOARD Vincenzo Adamo Massimo Aglietta Roberto Bianco Giovanni Brandi Marco Carini Leonardo Della Salda

Corrado Ficorella Francesco Grignani

Lorenzo Lo Muzio Patrizia Querzoli

Antonio Russo Marina Scarpelli

Silverio Tomao Giuseppe Tonini ORGANIZING SECRETARIAT

Giovanna Di Credico OFFICES

Consorzio Interuniversitario Nazionale per la Bio-Oncologia (CINBO) c/o Sezione di Oncologia Medica Università G. D’Annunzio - Via dei Vestini, 31

66100 Chieti - Italy Phone: +39 0871 3556732

Fax +39 0871 3556707 [email protected] PROVIDER ECM ID. 50

Strategie S.r.L. - Via Piave 110/7 - Pescara Phone: 085 74143 - Fax: 085 378220

[email protected] www.strategieonweb.it

CHALLENGES IN BREAST CANCER MANAGEMENT

November 22, 2019

SALA CONVEGNI

Centro Scienze dell’Invecchiamento e Medicina Traslazionale

(Ce.S.I.-Me.T.)

Via L. Polacchi 11/13

CHIETI

Directors

Teresa Gamucci Clara Natoli Patrizia Vici

CINBO

Consorzio Interuniversitario Nazionale per la Bio-Oncologia

Evento n. ECM 50-275093 Per Medici Chirurghi specialisti in:

ALLERGOLOGIA ED IMMUNOLOGIA CLINICA; EMATOLOGIA;

ENDOCRINOLOGIA; GENETICA MEDICA; ONCOLOGIA;

RADIOTERAPIA; CHIRURGIA GENERALE; CHIRURGIA PLASTICA E RICOSTRUTTIVA; GINECOLOGIA E OSTETRICIA; ANATOMIA PATOLOGICA; FARMACOLOGIA E TOSSICOLOGIA CLINICA;

LABORATORIO DI GENETICA MEDICA; MEDICINA NUCLEARE;

RADIODIAGNOSTICA.

Per Farmacisti (Farmacia ospedaliera). Per Biologi.

Crediti ECM: 7

Si ringrazia per il contributo incondizionato:

La partecipazione è gratuita.

Le iscrizioni si accettano in sede di evento.

Patrocinio richiesto:

Stampa Demagraf - Pescara

Educational School of Oncology - CINBO

Con il patrocinio di:

(2)

09.30 Registration & Welcome coffee 10.00 Objectives of the course

Teresa Gamucci, Clara Natoli, Patrizia Vici Session I

Moderators: Clara Natoli, Corrado Ficorella

10.10 Therapeutic approach to HER2+ breast cancer in the neoadjuvant and adjuvant setting

Patrizia Vici, Roma

10.30 Therapeutic approach to triple negative breast cancer in the neoadjuvant and adjuvant setting Teresa Gamucci, Roma

10.50 Discussants:

Maria Teresa Scognamiglio, Maria Mancini Session II

Moderators: Patrizia Vici, Nicola D’Ostilio

11.20 New imaging techniques for early breast cancer detection

Marzia Muzi, Ortona (CH)

11.40 Bone protection during adjuvant hormone therapy Francesco Pantano, Roma

12.00 Interactions between new systemic agents and radiotherapy for metastatic breast cancer Lucia Anna Ursini, Chieti

12.20 The GIM-13 trial: updates Giorgio Mustacchi, Trieste

12.40 Complementary medicine in breast cancer management

Ettore Cianchetti, Chieti 13. 00 Discussants:

Jamara Giampietro, Eriseld Krasniqi 13.30 Light lunch

Program

Maddalena Barba

[email protected] Roma

Fiamma Buttitta [email protected] Chieti

Katia Cannita [email protected] L’Aquila

Ettore Cianchetti [email protected] Chieti

Giuliana D’Auria

[email protected] Roma

Francesca Di Giandomenico [email protected] Ortona (CH)

Pietro Di Marino

[email protected] Chieti

Pia Di Stefano

[email protected] Pescara

Nicola D’Ostilio

[email protected] Lanciano (CH)

Corrado Ficorella

[email protected] L’Aquila

Teresa Gamucci

[email protected] Roma

Jamara Giampietro [email protected] Chieti

Antonino Grassadonia [email protected] Chieti

Laura Iezzi

[email protected] Giulianova (TE) Eriserld Krasniqi [email protected] Roma

Dimitri Luisi

[email protected] Pescara

Maria Mancini

[email protected] Lanciano (CH)

Giorgio Mustacchi [email protected] Trieste

Marzia Muzi

[email protected] Ortona (CH)

Clara Natoli [email protected] Chieti

Amedeo Pancotti [email protected] Teramo

Francesco Pantano [email protected] Roma

Laura Pizzuti

[email protected] Roma

Maria Teresa Scognamiglio [email protected] Ortona (CH)

Cinzia Solinas [email protected] Aosta

Liborio Stuppia [email protected] Chieti

Silverio Tomao

[email protected] Roma

Lucia Anna Ursini

[email protected] Chieti

Patrizia Vici

[email protected] Roma

Marinella Zilli [email protected] Chieti

Faculty

Session III

Moderators: Teresa Gamucci, Amedeo Pancotti, Dimitri Luisi 14.30 Therapeutic approach to HER2+ breast cancer in the

metastatic setting Giuliana D’Auria, Roma

14.50 The therapeutic approach to triple negative breast cancer in the metastatic setting

Laura Pizzuti, Roma

15.10 The growing role of CDK4-6 inhibitors in the therapeutic strategy of metastatic breast cancer: how to choose?

Katia Cannita, L’Aquila 15.30 Discussants:

Francesca Di Giandomenico, Laura Iezzi 16.00 Coffee break

Session IV

Moderators: Fiamma Buttitta, Maddalena Barba 16.20 New developments of immunotherapy

in breast cancer management Cinzia Solinas, Aosta

16.40 Trastuzumab biosimilars: therapeutic continuity, switch, interchangeability

Clara Natoli, Pietro Di Marino, Chieti

17.00 Germline mutations predisposing to breast cancer Liborio Stuppia, Chieti

17.20 PARP inhibitors in breast cancer management:

where we are?

Silverio Tomao, Roma

17.40 New drugs in clinical trials targeting breast cancer oncogenic pathways

Antonino Grassadonia, Chieti

18.00 Discussants: Marinella Zilli, Pia di Stefano 18.30 Closing remarks

Educational School of Oncology - CINBO (ESO-CINBO)

Riferimenti

Documenti correlati

IMPORTANCE The value of platinum-based adjuvant chemotherapy in patients with triple-negative breast cancer (TNBC) remains controversial, as does whether BRCA1 and BRCA2

Moderatori: Roberto Labianca (Bergamo), Stefano Cantafio (Prato) 15.00 Risk factors and adjuvant treatment of colon cancer in 2021. Samantha Di

- COVID-19 and cancer prognosis - David Pinato - COVID-19: Impact on Breast Cancer - Livia Giordano Chair Giancarlo Avanzi?. Lecture Psycologic Distress during the COVID-19 pandemic

Best Clinical International BJClub Award Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer (NEJM

Moderators: Nicola D’Ostilio, Luigi Schips 11.40 Prostate cancer diagnosis: screening. and novel diagnostic biomarkers Costantino

Moderators: Alessandra Gennari, Filippo Montemurro Early Breast Cancer Grazia Arpino.. Advanced Breast Cancer

Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta - analysis of randomized clinical trials.. Crit Rev

In breast cancer cell lines and in tumor breast cells, particularly those with a “triple negative” (TNBC, triple negative breast cancer) phenotype (so defined because tumor cells do